Analysis of ixabepilone exposure-response for neutropenia in patients with metastatic breast cancer

被引：1
|
作者：
Roy, A.
Zhu, H.
Cohen, M.
Zhang, L.
Pfister, M.
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] US FDA, Silver Spring, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.2511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exposure-response analysis for ixabepilone associated neutropenia.
    Cohen, M.
    Pfister, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S23 - S23
  • [2] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
    Doshi, Sameer
    Gisleskog, Per Olsson
    Zhang, Yilong
    Zhu, Min
    Oliner, Kelly S.
    Loh, Elwyn
    Ruixo, Juan Jose Perez
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2453 - 2461
  • [4] Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer
    Pena-Cabia, Silvia
    Royuela Vicente, Ana
    Ramos Diaz, Ruth
    Gutierrez Nicolas, Fernando
    Penalver Vera, Angela
    Siso Garcia, Isabel
    Hitt Sabag, Ricardo
    Garcia Lacalle, Concepcion
    Pena-Cabia, Ana
    Iglesias-Peinado, Irene
    Garcia Diaz, Benito
    Lopez-Martin, Ana
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 141
  • [5] Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer
    Krens, Stefanie D.
    van Erp, Nielka P.
    Groenland, Stefanie L.
    Moes, Dirk Jan A. R.
    Mulder, Sasja F.
    Desar, Ingrid M. E.
    van der Hulle, Tom
    Steeghs, Neeltje
    van Herpen, Carla M. L.
    BMC CANCER, 2022, 22 (01)
  • [6] Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
    Krens, S. D.
    van Erp, N. P.
    Groenland, S.
    Moes, D. J. A.
    Desar, I. M. E.
    Mulder, S. F.
    Van Der Hulle, T.
    Steeghs, N.
    Van Herpen, C. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S602 - S602
  • [7] Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer
    Sathe, Abhishek G.
    Diderichsen, Paul M.
    Fauchet, Floris
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 570 - 578
  • [8] EXPOSURE-RESPONSE (ER) ANALYSIS OF AXITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED THYROID CANCER (TC).
    Lam, L. H.
    Chang, A. T.
    Ruiz-Garcia, A.
    Ingrosso, A.
    Bycott, P.
    Pithavala, Y. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S16 - S16
  • [9] Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer
    Pena-Cabia, Silvia
    Royuela-Vicente, Ana
    Ramos-Diaz, Ruth
    Gutierrez-Nicolas, Fernando
    Garcia-Diaz, Benito
    Lopez-Martin, Ana
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 21 - 26
  • [10] Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
    Hirabatake, Masaki
    Mizuno, Tomoyuki
    Kato, Hironori
    Hashida, Tohru
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345